Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Aura Biosciences is asking shareholders to vote at a virtual Special Meeting on August 5, 2026 to approve two governance items.
First, Proposal No. 1 would amend the charter to increase authorized common shares from 150,000,000 to 500,000,000. Second, Proposal No. 2 would amend the 2021 Stock Option and Incentive Plan to include pre-funded warrants in the plan's annual "evergreen" share-count formula (effective for increases beginning January 1, 2027 through plan expiration in October 2031). The proxy discloses 103,436,416 shares outstanding as of June 12, 2026 and share-usage tables as of June 1, 2026. The board recommends a FOR vote on both proposals.
Aura Biosciences, Inc. reports a proposed sale of 37,500 shares of Common Stock represented by a restricted stock unit award granted under the company's 2021 Stock Option and Incentive Plan. The RSU award is dated 06/02/2025 and the Form 144 filing entry is dated 06/16/2026.
The entry lists the securities to be sold as Common Stock on Nasdaq and identifies the award as subject to vesting requirements under the 2021 plan.
Aura Biosciences, Inc. officer Anthony S. Gibney reported an automatic sale of common stock tied to tax withholding. On June 16, 2026, 12,824 shares were sold at $6.42 per share to cover tax obligations from vesting restricted stock units, leaving him with 265,354 directly held shares. The footnote states these sales were executed automatically and not at his discretion.
Aura Biosciences director Teresa Marie Bitetti received new equity awards as part of her compensation. She was granted 15,000 restricted stock units, each representing one share of common stock, and 30,000 stock options with an exercise price of $6.21 per share.
The RSUs and options each vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to her continued service. After the grant, she holds 36,000 shares of common stock directly, plus the newly awarded 30,000 options.
Aura Biosciences director Sapna Srivastava received new equity awards in the form of stock and options. She was granted 15,000 shares of Common Stock through a restricted stock unit (RSU) award and 30,000 stock options with an exercise price of $6.21 per share.
The RSUs and options each vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to her continued service. After the RSU grant, her direct Common Stock holdings total 38,500 shares, and she holds 30,000 options to buy additional shares.
Aura Biosciences, Inc. director David Michael Johnson reported new equity compensation awards and updated his holdings. He received 15,000 shares of Common Stock through a restricted stock unit (RSU) award under the 2021 Stock Option and Incentive Plan, which vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to continued service. He was also granted stock options for 30,000 shares of Common Stock at an exercise price of $6.21 per share, expiring June 11, 2036, with the same vesting schedule. After these awards, he directly holds 194,167 Common shares and 30,000 options, and indirectly holds additional shares through Velocity Capital Management LLC and the NEJ09 and NEJ12 irrevocable trusts where he is a trustee or sole member.
Aura Biosciences director Antony C. Mattessich received new equity awards. On June 11, 2026, he was granted 15,000 shares of Common Stock through a restricted stock unit award and now holds 38,500 Common Stock shares directly.
The RSUs were granted under the 2021 Stock Option and Incentive Plan, with each RSU representing one share of Common Stock. They vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continued service.
He was also granted stock options covering 30,000 shares of Common Stock at an exercise price of $6.21 per share. These options vest and become exercisable on the same earlier-of vesting schedule and expire on June 11, 2036.
Aura Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Common stock entitled to vote totaled 64,199,778 shares, with 52,784,744 shares present or represented by proxy.
Stockholders elected David Johnson and Teresa Marie Bitetti as Class II directors to serve until the 2029 Annual Meeting, with Johnson receiving 34,542,193 votes for and Bitetti receiving 40,526,332 votes for. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 52,752,601 votes for, 17,348 against and 14,795 abstentions, and no broker non-votes.
Aura Biosciences, Inc. reported that director and officer Natalie C. Holles received significant equity awards in the form of restricted stock units, performance RSUs and stock options. She was granted 553,844 RSUs as Inducement Awards, each representing one share of common stock, vesting in four equal annual installments beginning on April 15, 2027, subject to continued service.
She also received 600,118 performance RSUs as Inducement Awards that require both time-based vesting and achievement of a performance condition. These PRSUs vest in four equal annual installments commencing on April 15, 2027 and expire on the earlier of the sixth anniversary of the grant date or the date her service with the company ends, with any unvested awards then forfeited.
In addition, Holles was granted a stock option covering 2,169,103 shares of common stock at an exercise price of $7.3900 per share, expiring on May 19, 2036. Twenty-five percent of the option vests on April 30, 2027, with the remainder vesting pro rata in 36 monthly installments, subject to continued service. Following these grants, she directly owns 1,153,962 shares of common stock.
Aura Biosciences, Inc. ownership disclosure: a group of TCG Crossover entities and Chen Yu report shared beneficial ownership positions in Common Stock following an underwritten offering that closed on May 5, 2026.
The filing shows Chen Yu (through affiliated funds and GPs) holds 9,533,333 shares (listed as 9.9%) on the cover page and each TCG fund/entity is shown with ~4,766,666–4,766,667 shares (~5.0% each). The disclosure excludes aggregate 3,800,000 shares subject to Pre-Funded Warrants not exercisable within 60 days because of a 9.99% Beneficial Ownership Limitation. The filing cites a base share reference of 103,178,777 shares outstanding as of May 5, 2026, and an adjusted denominator of 96,255,907 derived by subtracting 6,922,870 shares assuming a repurchase described in the prospectus.